ArticleCancers2021
Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01596790 (Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment
Who cites it
12 citing papers in PubMed.
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- Review
- Circulating tumour cells in gastrointestinal cancers: food for thought?British journal of cancer · 2023Review
- Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility.International journal of molecular sciences · 2022Review
- Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer.Cancers · 2022Article
- Optimal whole blood dilution protocol for preprocessing samples prior to circulating tumor cell capture by size-based isolation.Journal of clinical laboratory analysis · 2022Article
- An Editorial View on the Special Issue "Colorectal Cancers: From Present Problems to Future Solutions".Cancers · 2022Article
- Advances in the Biology, Detection Techniques, and Clinical Applications of Circulating Tumor Cells.Journal of oncology · 2022Review
- Cell-free DNA as a biomarker in cancer.Extracellular vesicles and circulating nucleic acids · 2022Review
- Liquid Biopsy and Primary Brain Tumors.Cancers · 2021Review
- Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCirculating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with EPISPOT, a functional assay that detects only viable CTCs, and with the CellSearch
methodsTreatment-naive patients with mCRC and measurable disease (RECIST criteria 1.1) received FOLFIRI-bevacizumab until progression or unacceptable toxicity. CTCs in peripheral blood were enumerated at D
resultsWith the EPISPOT assay, at least 1 viable CTC was detected in 21% (D
conclusionsCTC detection at D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.